<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>前免疫</title><link/>https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%20%5BNLMID%5D&amp;fc=none&amp;ff = 20250 = 2.18.0.post9+E462414<description>前免疫：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%5BNLMID%5D&amp;fc=None&amp;ff=20250129170938&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=journals&amp;utm_content=101560960&amp;v=2.18.0.post9+e462414" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate>星期三，2025年1月29日22:09:41 +0000</lastbuilddate><pubDate> Wed, 29 Jan 2025 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title> MSI状态不同的结直肠癌和当前治疗策略的肿瘤免疫微环境的特征</title><link/>https://pubmed.ncbi.nlm.nih.gov/39877377/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250129170938&amp;v=2.18.0.post9+e462414<description>结直肠癌（CRC）仍然是全球与癌症相关死亡率的重要原因。尽管在手术，化学疗法和放疗方面取得了进步，但这些常规疗法的有效性受到限制，尤其是在晚期病例中。因此，迫切需要过渡到新型治疗。免疫疗法，尤其是免疫检查点抑制剂（ICIS），已经显示出有望改善CRC患者的预后。值得注意的是，缺乏不匹配修复（DMMR）或...的患者</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月14日； 15：1440830。 doi：10.3389/fimmu.2024.1440830。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结直肠癌（CRC）仍然是全球与癌症相关死亡率的重要原因。尽管在手术，化学疗法和放疗方面取得了进步，但这些常规疗法的有效性受到限制，尤其是在晚期病例中。因此，迫切需要过渡到新型治疗。免疫疗法，尤其是免疫检查点抑制剂（ICIS），已经显示出有望改善CRC患者的预后。值得注意的是，缺乏不匹配修复（DMMR）或微卫星不稳定性高（MSI-H）肿瘤的患者通常会受益于ICIS，而大多数CRC病例（表现出熟练的不匹配修复（PMMR）或微片状稳定（MSS）状态，通常显示对这种方法的抵抗力。假定MSI表型会导致肿瘤微环境（TME）的某些变化，从而触发抗肿瘤免疫力并导致对免疫疗法的反应。了解TME相对于MSI状态的这些差异对于制定更有效的治疗策略至关重要。这篇综述概述了CRC中的TME组件，并探讨了旨在增强MSS CRC中ICI功效的当前方法。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39877377/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">39877377</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11772360/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">PMC11772360</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1440830>10.3389/fimmu.2024.1440830</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39877377</guid><pubDate> Wed, 29 Jan 2025 06:00:00 -0500</pubDate><dc:creator>金王</dc:creator><dc:creator>min yu</dc:creator><dc:creator> Shuang Zhang</dc:creator><dc:date> 2025-01-29</dc:date><dc:source>免疫学领域</dc:source><dc:title>MSI状态不同的结直肠癌和当前治疗策略的肿瘤免疫微环境的特征</dc:title><dc:identifier>PMID：39877377</dc:identifier><dc:identifier> PMC：PMC11772360</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1440830</dc:identifier></item><item><title>从疼痛到脑膜炎：细菌劫持伤害感受器来促进脑膜炎</title><link/>https://pubmed.ncbi.nlm.nih.gov/39877376/?utm_source = chrome&amp;utm_medium = rsss＆utm_campaign = Journals&amp;utm_campaign = Journals&amp;utm_content = 101560960&amp;fc=none&amp;fc=none&amp;ff = none＆fff = = = = = = = = = = = = = = = = = = = = = = = = = == 4<description>细菌性脑膜炎是中枢神经系统（CNS）严重而威胁生命的感染，主要是由肺炎链球菌和脑膜炎奈瑟氏菌引起的。这种情况具有高死亡率和严重的神经系统后遗症的高风险，例如认知障碍和癫痫。疼痛是脑膜炎的主要特征，是由于炎症性介质或细菌毒素激活伤害感受器感觉神经元的原因。这些伤害感受器在脑膜中大量存在，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月14日； 15：1515177。 doi：10.3389/fimmu.2024.1515177。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">细菌性脑膜炎是中枢神经系统（CNS）严重而威胁生命的感染，主要是由<i>肺炎链球菌</i>和<i>脑膜炎奈瑟氏菌</i>引起的。这种情况具有高死亡率和严重的神经系统后遗症的高风险，例如认知障碍和癫痫。疼痛是脑膜炎的主要特征，是由于炎症性介质或细菌毒素激活伤害感受器感觉神经元的原因。这些伤害感受器在脑膜中大量存在，引发了影响宿主免疫反应的神经免疫性信号通路。然而，细菌劫持这些伤害感受器促进中枢神经系统侵袭和加剧该疾病的机制仍然很众所周知。这篇综述研究了细菌与脑膜伤害感受器之间的相互作用，重点是通过离子通道的直接和间接激活，例如瞬态受体电位香草素-1（TRPV1）和瞬态受体电位Ankyrin 1（TRPA1），或通过释放神经肽的释放降钙素基因相关肽（CGRP）。这些相互作用通过抑制巨噬细胞活性和中性粒细胞募集来抑制免疫防御，从而促进了细菌的生存和侵袭CNS。了解该神经免疫性轴可能会通过增强宿主防御和减轻疼痛来打开潜在的治疗靶标，以治疗细菌性脑膜炎。使用先进方法的进一步研究对于阐明伤害感受器介导的免疫调节在该疾病中的作用至关重要。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39877376/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">39877376</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11772308/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">PMC11772308</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1515177>10.3389/fimmu.2024.1515177</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39877376</guid><pubDate> Wed, 29 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Huazhen Liu</dc:creator><dc:creator> Xingxing Kong</dc:creator><dc:creator> Yuqin Zeng</dc:creator><dc:creator> Jinyun Chen</dc:creator><dc:creator> Zhanpeng Chen</dc:creator><dc:creator> Lanlan Liu</dc:creator><dc:creator> Quan MA</dc:creator><dc:creator> Xuhui Liu</dc:creator><dc:creator> shuihua lu</dc:creator><dc:date> 2025-01-29</dc:date><dc:source>免疫学领域</dc:source><dc:title>从疼痛到脑膜炎：细菌劫持伤害感受器来促进脑膜炎</dc:title><dc:identifier>PMID：39877376</dc:identifier><dc:identifier> PMC：PMC11772308</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1515177</dc:identifier></item><item><title>用不同剂量的混合辐射诱导CCL17募集CD8 &lt;SUP>;+&lt;/sup>; T细胞以在非小细胞肺癌中发挥抗肿瘤作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/39877375/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250129170938&amp;v=2.18.0.post9+e462414<description>结论：我们的研究表明，20GY和6GY的联合应用可以增强小鼠中肿瘤CD8^（+）T细胞的浸润，并提高免疫疗法的有效性。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月14日； 15：1508007。 doi：10.3389/fimmu.2024.1508007。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：不同剂量的放疗（RT）对肿瘤免疫产生了不同的影响，尽管确切的照射方法仍然未知。这项研究试图阐明将不同剂量的RT与免疫检查点抑制剂（ICI）组合对肿瘤中CD8 <sup>+</sup> T细胞浸润的影响，从而增加了抗肿瘤反应。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：构建具有高剂量照射和低剂量照射的双侧肺癌肿瘤的小鼠模型，RNA转录组测序数据的分析以及暴露于各种剂量的肿瘤的免疫组织化学验证，指导了最佳的低剂量辐射方案的选择。随后，在整合免疫检查点抑制剂（ICIS）治疗后，通过免疫组织化学（IHC）和流式细胞仪（FCM）确定了肿瘤内免疫细胞内的免疫细胞的浸润。最后，通过生物信息学分析和实验验证，研究了加强抗肿瘤免疫反应的潜在策略。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：与单独使用20GY对原发性肿瘤的施用相比，补充了针对潜线肿瘤的6GY产生的潜线反应更为明显。 20GY，6GY和ICIS的协同作用显着提高了ICIS的效率。根据IHC和FCM研究的发现，三重治疗组表现出免疫细胞浸润到肿瘤中的渗透率升高，这在很大程度上归因于在这些辐照方案下肿瘤中CCL17的表达增强，随后绘制了CD8+ T细胞以浸润CD8+ T细胞以浸润CD8+ T细胞。肿瘤部位，发挥细胞毒性作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们的研究表明，20GY和6GY的联合应用可以增强小鼠中肿瘤CD8 <sup>+</sup> T细胞的浸润，并提高免疫疗法的有效性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39877375/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">39877375</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11772420/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">PMC11772420</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1508007>10.3389/fimmu.2024.1508007</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39877375</guid><pubDate> Wed, 29 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Liuying Huang</dc:creator><dc:creator>王二人</dc:creator><dc:creator>大量XU</dc:creator><dc:creator> Danqi Qian</dc:creator><dc:creator> Yulin Cao</dc:creator><dc:creator>小吴</dc:creator><dc:creator>梁明</dc:creator><dc:creator>朱尼·唐</dc:creator><dc:creator>Zhaohui Huang</dc:creator><dc:creator>元阴</dc:creator><dc:creator>Leyuan Zhou</dc:creator><dc:date> 2025-01-29</dc:date><dc:source>免疫学领域</dc:source><dc:title>用不同剂量的混合辐射诱导CCL17募集CD8 &lt;SUP>;+&lt;/sup>; T细胞以在非小细胞肺癌中发挥抗肿瘤作用</dc:title><dc:identifier>PMID：39877375</dc:identifier><dc:identifier> PMC：PMC11772420</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1508007</dc:identifier></item><item><title>多发性硬化症中的少突胶质细胞成熟与少突胶质细胞的受损相关</title><link/>https://pubmed.ncbi.nlm.nih.gov/39877374/?utm_source = chrome&amp;utm_medium = rsss＆utm_campaign = Journals&amp;utm_campaign = Journals&amp;utm_content = 101560960＆fc = none＆fc=none&amp;ff = none＆fff = = = = = = = = = = = = = = = = = = = = = = = = = = == 4<description>简介：在多发性硬化症（MS）中，可以作为内源性修复机制发生脱髓鞘轴突的再髓，但MS个体和病变之间的疗效也有所不同。驱动再髓的分子和细胞机制仍然鲜为人知。在这里，我们研究了MS中的小胶质细胞激活与再生性活性之间的关系。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月14日； 15：1522381。 doi：10.3389/fimmu.2024.1522381。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：在多发性硬化症（MS）中，可以作为内源性修复机制发生脱髓鞘轴突的再髓，但MS个体和病变之间的疗效也有所不同。驱动再髓的分子和细胞机制仍然鲜为人知。在这里，我们研究了MS中的小胶质细胞激活与再生性活性之间的关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们将再生（CD163 <sup>+</sup> ）和炎症（Inos <sup>+</sup> ）小胶质细胞与BCAS1 <sup>+</sup>少突胶质细胞相关联（INOS +）小胶质细胞，分为高或低雷格潜在潜在潜在的脑供体的早期阶段（&lt;3个过程）和晚期（≥3个过程）和晚期（≥3个过程）在透明体病变和活性病变中，具有分支/变形虫（非泡沫状）或泡沫小胶质细胞。根据尸检时的延期病变的比例，包括了一组MS供体归类为有效延期供体（ERD; n = 25）或不良再生供体（PRD; n = 17）的队列。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果和讨论：我们假设来自ERD的透明和活性非泡沫病变中的CD163 <sup>+</sup>小胶质细胞和BCAS1 <sup>+</sup>少突胶质细胞，以及较少的BCAS1 + bcas1 <sup>+</sup>少突胶质细胞的iNOS <sup>+</sup>小胶质细胞中的浓郁泡沫病变中的含量较少。但是，对于CD163 <sup>+</sup>小胶质细胞，在MS病变和MS供体组之间未观察到差异。与我们的假设一致，我们发现，与再生病变内的ERD相比，PRD的Inos <sup>+</sup>小胶质细胞显着增加。 MS病变，与透明染色的病变相比，在非泡沫或泡沫小胶质细胞的活性病变中检测到更多的晚期BCAS1 <sup>+</sup>少突胶质细胞。尽管在MS病变之间没有发现早期BCAS1 <sup>+</sup>少突胶质细胞的差异，但我们确实发现PRDS与ERDS的早期BCAS1 <sup>+</sup>少突胶质细胞在remyele后病变中的早期阶段更大。有趣的是，在Inos <sup>+</sup>小胶质细胞和早期BCAS1 <sup>+</sup>少突胶质细胞的存在之间鉴定出正相关。这些发现表明，遇到炎症性小胶质细胞的早期BCAS1 <sup>+</sup>少突胶质细胞的成熟受损，可能是MS中的再髓样缺陷和不成功的病变修复的基础。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39877374/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">39877374</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11772157/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">PMC11772157</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1522381>10.3389/fimmu.2024.1522381</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39877374</guid><pubDate> Wed, 29 Jan 2025 06:00:00 -0500</pubDate><dc:creator> JQ Alida Chen</dc:creator><dc:creator>丹尼斯·韦弗（Dennis d Wever）</dc:creator><dc:creator> Niamh B McNamara</dc:creator><dc:creator> Morjana Bourik</dc:creator><dc:creator>乔斯特·闷闷</dc:creator><dc:creator>约翰·哈曼（JörgHamann）</dc:creator><dc:creator>英格·休欣</dc:creator><dc:date>2025-01-29</dc:date><dc:source>免疫学领域</dc:source><dc:title>多发性硬化症中的少突胶质细胞成熟与少突胶质细胞的受损相关</dc:title><dc:identifier>PMID：39877374</dc:identifier><dc:identifier> PMC：PMC11772157</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1522381</dc:identifier></item><item><title>阿尔茨海默氏病的线粒体功能障碍：未来靶向疗法的关键边界</title><link/>https://pubmed.ncbi.nlm.nih.gov/39877373/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250129170938&amp;v=2.18.0.post9+e462414<description>阿尔茨海默氏病（AD）是最常见的神经退行性疾病，占全球痴呆症病例的70％。患者逐渐表现出认知能力下降，例如记忆力丧失，失语和人格和行为变化。研究表明，线粒体功能障碍在AD的发作和进展中起关键作用。线粒体功能障碍主要导致氧化应激增加，线粒体动力学失衡，线粒体受损和... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月14日； 15：1484373。 doi：10.3389/fimmu.2024.1484373。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">阿尔茨海默氏病（AD）是最常见的神经退行性疾病，占全球痴呆症病例的70％。患者逐渐表现出认知能力下降，例如记忆力丧失，失语和人格和行为变化。研究表明，线粒体功能障碍在AD的发作和进展中起关键作用。线粒体功能障碍主要导致氧化应激增加，线粒体动力学失衡，线粒体受损和线粒体基因组异常。这些线粒体异常与淀粉样蛋白β和tau蛋白质病理学密切相关，共同加速了神经退行性过程。这篇综述总结了线粒体在AD开发中的作用，这是最新的研究进展，并探讨了靶向线粒体的AD治疗策略的潜力。靶向线粒体相关的途径可能会显着改善未来AD患者的生活质量。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39877373/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">39877373</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11772192/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">PMC11772192</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1484373>10.3389/fimmu.2024.1484373</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39877373</guid><pubDate> Wed, 29 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Shuguang Wang</dc:creator><dc:creator> Zuning Liao</dc:creator><dc:creator> Zhang Qiying</dc:creator><dc:creator> Xinyuan Han</dc:creator><dc:creator> ChangQing Liu</dc:creator><dc:creator>金王</dc:creator><dc:date>2025-01-29</dc:date><dc:source>免疫学领域</dc:source><dc:title>阿尔茨海默氏病的线粒体功能障碍：未来靶向疗法的关键边界</dc:title><dc:identifier>PMID：39877373</dc:identifier><dc:identifier> PMC：PMC11772192</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1484373</dc:identifier></item><item><title>巨噬细胞在OSCC进展中的影响</title><link/>https://pubmed.ncbi.nlm.nih.gov/39877372/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250129170938&amp;v=2.18.0.post9+e462414<description>巨噬细胞是肿瘤微环境（TME）内的至关重要的免疫细胞，参与调节肿瘤增殖，侵袭，转移，ECM重塑，血管生成和免疫抑制。尽管越来越多的实验证据和临床数据表明，巨噬细胞参与口服鳞状细胞癌（OSCC）的发作和进展，但与巨噬细胞相关的OSCC的确切发病机理尚未完全阐明。增强了分子的知识... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月14日； 15：1517886。 doi：10.3389/fimmu.2024.1517886。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">巨噬细胞是肿瘤微环境（TME）内的至关重要的免疫细胞，参与调节肿瘤增殖，侵袭，转移，ECM重塑，血管生成和免疫抑制。尽管越来越多的实验证据和临床数据表明，巨噬细胞参与口服鳞状细胞癌（OSCC）的发作和进展，但与巨噬细胞相关的OSCC的确切发病机理尚未完全阐明。对OSCC中涉及巨噬细胞的分子机制的知识增强，将有助于创建针对巨噬细胞的治疗方法。这篇综述概述了巨噬细胞在OSCC中的肿瘤和抗肿瘤作用，强调了OSCC细胞与巨噬细胞之间的相互作用。它可以为建立以巨噬细胞为中心的复杂监管网络提供理论基础，并探索OSCC的新型治疗策略。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39877372/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">39877372</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11772471/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">PMC11772471</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1517886>10.3389/fimmu.2024.1517886</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39877372</guid><pubDate> Wed, 29 Jan 2025 06:00:00 -0500</pubDate><dc:creator>小丹</dc:creator><dc:creator>Chunling Dong</dc:creator><dc:creator>博李</dc:creator><dc:date>2025-01-29</dc:date><dc:source>免疫学领域</dc:source><dc:title>巨噬细胞在OSCC进展中的影响</dc:title><dc:identifier>PMID：39877372</dc:identifier><dc:identifier> PMC：PMC11772471</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1517886</dc:identifier></item><item><title>病例报告：用化学疗法治疗的T细胞急性淋巴细胞白血病，然后使用逆转录病毒载体进行抗CD7 CAR-T细胞</title><link/>https://pubmed.ncbi.nlm.nih.gov/39877371/?utm_source = chrome&amp;utm_medium = rsss＆utm_campaign = Journals&amp;utm_campaign = journals&amp;utm_contt = 101560960＆fc = none＆fc = none&amp;ffcuff = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = == 4<description>靶向CD7的嵌合抗原受体T（CAR-T）细胞疗法在治疗复发/难治性T细胞急性淋巴细胞白血病（T-ALL）方面表现出了很大的希望。在这项研究中，我们报道了一例34岁的男性患有T-All的男性患者，该患者最终在多种高强度化疗后产生了多线耐药性和难治性。经过医师评估后，该患者接受了同种异体造血干细胞移植（Allo-HSCT）。然后，病人... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月14日； 15：1519055。 doi：10.3389/fimmu.2024.1519055。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">靶向CD7的嵌合抗原受体T（CAR-T）细胞疗法在治疗复发/难治性T细胞急性淋巴细胞白血病（T-ALL）方面表现出了很大的希望。在这项研究中，我们报道了一例34岁的男性患有T-All的男性患者，该患者最终在多种高强度化疗后产生了多线耐药性和难治性。经过医师评估后，该患者接受了同种异体造血干细胞移植（Allo-HSCT）。然后，患者在完全缓解（CR）中保持四个月，然后以26.64％的嵌合率复发，因此在化学疗法减轻肿瘤负担后，他接受了同种异体抗CD7 CAR-T细胞的治疗。 CAR-T产品是基于逆转录病毒载体（RV）的新型抗CD7 CAR-T。输注后，患者在抗CD7 CAR-T输液后的1个月内达到了CR，并且已持续9个月。细胞因子释放综合征（CRS）1是经历的，而未发现与免疫效应细胞相关的神经毒性综合征（ICANS）。此外，在第6天，汽车拷贝数在350、758份/μg的峰值。该病例报告用抗CD7 CAR-T细胞对T-ALL进行临床治疗，并使用逆转录病毒载体制备，而没有基因编辑并与化学疗法结合使用，该病毒疗法是证明基于RV的抗CD7 CAR-T细胞对三重fractory T-​​ALL患者具有良好的治疗作用和高安全性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39877371/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">39877371</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11772494/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">PMC11772494</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1519055>10.3389/fimmu.2024.1519055</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39877371</guid><pubDate> Wed, 29 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Huanhuan Zhou</dc:creator><dc:creator> Wenxiang Zhu</dc:creator><dc:creator> Qihong MA</dc:creator><dc:creator> Ning Liu</dc:creator><dc:creator> Mengdi Jin</dc:creator><dc:creator> Yaru Feng</dc:creator><dc:creator>利蒙赵</dc:creator><dc:creator>鲁太阳</dc:creator><dc:creator>longyou li</dc:creator><dc:creator> Huaxiu li</dc:creator><dc:creator> Yuanyuan Shi</dc:creator><dc:creator>江恩·王</dc:creator><dc:creator>Liqiong Liu</dc:creator><dc:creator> Zhi guo</dc:creator><dc:date> 2025-01-29</dc:date><dc:source>免疫学领域</dc:source><dc:title>病例报告：用化学疗法治疗的T细胞急性淋巴细胞白血病，然后使用逆转录病毒载体进行抗CD7 CAR-T细胞</dc:title><dc:identifier>PMID：39877371</dc:identifier><dc:identifier> PMC：PMC11772494</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1519055</dc:identifier></item><item><title> CD56 &lt;sup>; Bright &lt;/sup>; NK细胞的转录特征预测膀胱癌的有利预后</title><link/>https://pubmed.ncbi.nlm.nih.gov/39877370/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250129170938&amp;v=2.18.0.post9+e462414<description>人类天然杀伤（NK）细胞可以分为两个功能性亚群，但这些CD56^（BRIGHT）和CD56^（DIM）NK细胞在抗肿瘤免疫力中的临床意义仍然很大程度上尚未得到探索。我们确定了CD56^（BRIGHT）和CD56^（DIM）NK细胞的基因特征的相对丰度，以及来自癌症基因组膀胱膀胱癌数据集（TCGA-BLCA）的患者肿瘤转录组中的3种基质和18种其他免疫细胞类型。 。使用这种计算方法，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月14日； 15：1474652。 doi：10.3389/fimmu.2024.1474652。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">人类天然杀手（NK）细胞可以分为两个功能子集，但是这些CD56 <sup>Bright</sup>和CD56 <sup>DIM</sup> NK细胞在抗肿瘤免疫中的临床意义仍然很大程度上尚未探索。我们确定了CD56 <sup>Bright</sup>和CD56 <sup>DIM</sup> NK细胞的基因特征的相对丰度，以及来自癌症基因组膀胱膀胱癌数据集（TCGA-BLCA）的患者肿瘤转录组中的3种基质和其他18种免疫细胞类型。使用这种计算方法，CD56<sup>明亮的</sup>NK细胞被预测为更丰富的肿瘤浸润NK子集，它也与改善患者预后有关。使用用于成熟的髓样树突状细胞（MDC）和CD8 <sup>+</sup>效应记忆T细胞（T <sub>EM</sub> ）的基因特征，预测了类似的有利生存趋势，并在BLCA肿瘤微环境中揭示了潜在的CD56<sup>明亮的CD56明亮的</sup>NK-MDC-CD8 <sup>+</sup> T细胞串扰。编码激活NK细胞受体NKG2D，NKP44，CD2和CD160的转录本的表达显示出正生存趋势与CD56<sup>明亮的</sup>NK细胞浸润。包括Hobit，IRF3和STAT2在内的转录因子也与CD56<sup>明亮的</sup>NK细胞丰度相关。此外，发现与CD56 <sup>Bright</sup> NK和CD8 <sup>+</sup> T <sub>EM</sub>细胞特征相关的HOBIT依赖性组织居住计划与有利的BLCA患者存活有关。总体而言，我们的研究突出了CD56<sup>明亮</sup>NK细胞在BLCA患者预后的重要性。我们的发现促进了对NK细胞抗肿瘤反应的更好理解，这些反应最终可能导致有希望的NK和T细胞基于BLCA的疗法的发展。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39877370/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">39877370</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11772185/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">PMC11772185</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1474652>10.3389/fimmu.2024.1474652</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39877370</guid><pubDate> Wed, 29 Jan 2025 06:00:00 -0500</pubDate><dc:creator> MD Abdullah Al Kamran Khan</dc:creator><dc:creator>亚历山大·詹姆斯·塞奇威克（Alexander James Sedgwick）</dc:creator><dc:creator> Yuhan Sun</dc:creator><dc:creator>朱利安·普维安（Julian P Vivian）</dc:creator><dc:creator>亚历山德拉·J·科贝特（Alexandra J Corbett）</dc:creator><dc:creator> Riccardo Dolcetti</dc:creator><dc:creator> Theo Mantamadiotis</dc:creator><dc:creator> Stefano Mangiola</dc:creator><dc:creator>亚历山大·戴维·巴罗（Alexander David Barrow）</dc:creator><dc:date> 2025-01-29</dc:date><dc:source>免疫学领域</dc:source><dc:title>CD56 &lt;sup>; Bright &lt;/sup>; NK细胞的转录特征预测膀胱癌的有利预后</dc:title><dc:identifier>PMID：39877370</dc:identifier><dc:identifier> PMC：PMC11772185</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1474652</dc:identifier></item><item><title>线性Iga大胆皮肤病 - 华沙​​的五十年经验</title><link/>https://pubmed.ncbi.nlm.nih.gov/39877369/?utm_source=chrome&amp;utm_medium = rsss＆utm_campaign = Journals&amp;utm_campaign = Journals&amp;utm_contt = 101560960＆fc=none&amp;fc=none&amp;ffc=none&amp;fff = = = = = = = = = = = = = = = = = = = = = = = = = = == 4<description>线性IgA大胆皮肤病（LABD）是一种罕见的亚皮下泡沫，其特征是通过直接免疫荧光（DIF）在基底膜区（BMZ）存在线性IGA沉积物（BMZ）。该实体首先是由波兰华沙疾病中心的Chorzelski和Jablonska描述的。该疾病会影响儿童和成人，在临床图片和过程中，他们在这种情况下有所不同。在波兰有粘膜膜受累的波兰患者中，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月14日； 15：1478318。 doi：10.3389/fimmu.2024.1478318。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">线性IgA大胆皮肤病（LABD）是一种罕见的亚皮下泡沫，其特征是通过直接免疫荧光（DIF）在基底膜区（BMZ）存在线性IGA沉积物（BMZ）。该实体首先是由波兰华沙疾病中心的Chorzelski和Jablonska描述的。该疾病会影响儿童和成人，在临床图片和过程中，他们在这种情况下有所不同。在具有LABD粘膜受累的波兰患者中，尽管有一个病例，但据报道，循环的IgG和IgA抗体对LAD-1抗原的循环症状和结膜严重疤痕。在IgA-尿液溶液易术（EBA）中也观察到严重的粘膜受累。从免疫学上讲，LABD的特征是循环的IgA抗体针对抗原BP180的几种表位：LAD-1，97KD，NC16A。其他BMZ抗原，例如BP230，层粘连蛋白332，VII型胶原蛋白或P200型。我们首次发表了由IGA介导的抗P200KD pemphigoid的案例。我们的免疫电子显微镜研究表明，LABD血清识别的表位是在Lamina Lucida中定位的。抗原异质性，IgA抗体的低滴度以及某些抗原（LAD-1，P200KD）的市售测试缺乏可诊断的诊断，在许多情况下具有挑战性。正在争论这些情况是LABD的亚型还是它们代表单独的实体（IgA-P200 pemphigoid，Iga-MMP或Iga-Eba）。由于它们在临床过程中，粘膜受累，共存疾病，对治疗的反应和预后有所不同，因此它们的分化是强制性的。在文献中，有许多病例具有无法检测到的循环IgA抗体，其中仅基于DIF识别LABD。为了避免误诊，应使用更复杂的方法，例如直接免疫元素显微镜（IEM），这是一种耗时的技术。 IEM的替代方法可能是：a）分析BMZ锯齿模式，b）泡的免疫荧光图，c）直接盐分裂（患者）皮肤，d）通过激光扫描共焦显微镜进行荧光覆盖抗原映射。后者的两种方法是由作者几年前建立的，它们允许精确诊断（即，IGA-EBA的分化LABD），适当的治疗开始和对IGA介导的预后评估。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39877369/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">39877369</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11772161/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">PMC11772161</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1478318>10.3389/fimmu.2024.1478318</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39877369</guid><pubDate> Wed, 29 Jan 2025 06:00:00 -0500</pubDate><dc:creator> CEZARY KOWALEWSKI</dc:creator><dc:creator> Katarzyna Wozniak</dc:creator><dc:date> 2025-01-29</dc:date><dc:source>免疫学领域</dc:source><dc:title>线性Iga大胆皮肤病 - 华沙​​的五十年经验</dc:title><dc:identifier>PMID：39877369</dc:identifier><dc:identifier> PMC：PMC11772161</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1478318</dc:identifier></item><item><title>命名衍生的免疫 - 炎症 - 营养评分可以作为头颈部鳞状细胞癌患者的新预后指标</title><link/>https://pubmed.ncbi.nlm.nih.gov/398777368/?utm_source=chrome&amp;utm_medium = rsss＆utm_campaign = Journals&amp;utm_campaign = journals&amp;utm_content = 101560960＆fc=none&amp;fc=none&amp;fc=none&amp;fff = = = = = = = = = = = = = = = = = = = = = = = = = = = == 4<description>结论：SIIN评分是一种有希望的预后工具，它整合了免疫，炎症和营养因素，以预测HNSCC患者的临床结果。与现有标记相比，它提供了增强的预测精度，并有可能指导个性化的治疗策略和临床决策。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月14日； 15：1500525。 doi：10.3389/fimmu.2024.1500525。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：这项研究旨在创建和验证一种新型的系统免疫 - 炎症 - 舒适（SIIN）评分，以为头部和颈部鳞状细胞癌（HNSCC）患者提供非侵入性和准确的预后工具。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在2008年至2017年期间，有259名诊断为Xi&#39;an Jiotong大学第一位分支机构医院HNSCC的参与者包括在这项回顾性研究中。将患者分配给训练（n = 181）和验证（n = 78）。采用了套索Cox回归模型来识别构建SIIN列图的重要生物标志物，并从该nom图中创建SIIN评分。通过利用接收器操作特征（ROC）分析，Kaplan-Meier生存分析，COX比例危害回归模型，校准和DCA曲线来评估SIIN评分的预后精度。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: The SIIN score was formulated based on six biomarkers-platelet-lymphocyte ratio (PLR), prognostic nutritional index (PNI), systemic immune-inflammation index (SII), albumin-bilirubin index (ALBI), fibrinogen (FIB) and monocyte通过LASSO回归分析确定计数。 （1）3年和5年OS的SIIN评分表现出优异的预测值，在ROC曲线（AUC）值为0.736和0.700下实现面积。对于无复发生存（RFS），3年的AUC值为0.752，而0.701 5年RFS为0.752，如训练集中所评估。在两个队列中，SIIN评分在两个队列中被证实为独立的预后因素，与不良临床病理学结果均显示出很强的相关性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：SIIN评分是一种有希望的预后工具，它整合了免疫，炎症和营养因素，以预测HNSCC患者的临床结果。与现有标记相比，它提供了增强的预测精度，并有可能指导个性化的治疗策略和临床决策。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39877368/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">39877368</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11772279/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">PMC11772279</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1500525>10.3389/fimmu.2024.1500525</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39877368</guid><pubDate> Wed, 29 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Wen Yan Wang</dc:creator><dc:creator> Yue Chen</dc:creator><dc:creator>钱陈</dc:creator><dc:creator>香港太阳</dc:creator><dc:creator>nuo-xuan niu</dc:creator><dc:creator>洪李</dc:creator><dc:creator>Yu-dan cao</dc:creator><dc:creator> yan-xia bai</dc:creator><dc:creator>西安·李</dc:creator><dc:date>2025-01-29</dc:date><dc:source>免疫学领域</dc:source><dc:title>命名衍生的免疫 - 炎症 - 营养评分可以作为头颈部鳞状细胞癌患者的新预后指标</dc:title><dc:identifier>PMID：39877368</dc:identifier><dc:identifier> PMC：PMC11772279</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1500525</dc:identifier></item><item><title>鲤鱼VIII抗体相关相关的自身免疫性小脑共济失调，&lt;em>; &lt;em>;支原体肺炎&lt;/em>;感染：病例报告</title><link/>https://pubmed.ncbi.nlm.nih.gov/39877367/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250129170938&amp;v=2.18.0.post9+e462414<description>自身免疫性性共济失调（ACA）是由自身免疫反应诱导的小脑综合征，其发作是由恶性肿瘤，原始感染和麸质过敏引起的。它的临床症状包括步态障碍，肢体共济失调，构音障碍和吞咽困难。根据中国专家关于2024年自身免疫性脑炎的诊断和管理的共识，ACA的诊断基于以下几点：1。疾病的亚急性或急性发作，小脑综合征作为... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年1月14日； 15：1480212。 doi：10.3389/fimmu.2024.1480212。环保2024。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">自身免疫性性共济失调（ACA）是由自身免疫反应诱导的小脑综合征，其发作是由恶性肿瘤，原始感染和麸质过敏引起的。它的临床症状包括步态障碍，肢体共济失调，构音障碍和吞咽困难。根据<i>中国专家在2024年自身免疫性脑炎的诊断和管理方面的共识</i>，ACA的诊断基于以下几点：1。疾病的亚急性或急性发作，小脑综合征作为主要表现； 2。疾病早期（三个月内）的颅磁共振成像（MRI）并未显示出小脑和脑干的显着萎缩。 3。存在以下任一个：1）血清和/或脑脊液基于细胞的阳性抗脑抗体抗体（CBA），2）至少存在以下两种：①患者或一级相对相对相对具有自身免疫性疾病的病史，②脑脊液白细胞>; 5×10 <sup>6</sup> /L，或者对脑脊液特异性寡聚型带呈阳性，基于组织的寡聚型测定法（TBA）揭示了purkinje细胞抗体的特征性荧光形式，以及purkinje细胞抗体的特征性荧光形式，④全身性自身免疫性疾病相关的抗体；和4。没有其他疾病。目前，与碳酸酐酶相关蛋白VIII（Carp VIII）的阳性结果相关的ACA实例较少。该抗体在卵巢癌，乳腺癌或黑色素瘤的成年人中检测到了三例病例报告，并且没有关于这种抗体的报告。此外，越来越多地报道了与支原体肺炎感染相关的神经系统疾病。因此，需要进一步研究这种感染与自身免疫性脑炎抗体之间的相关性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/39877367/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">39877367</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11772169/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">PMC11772169</a> | doi： <a href=https://doi.org/10.3389/fimmu.2024.1480212>10.3389/fimmu.2024.1480212</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：39877367</guid><pubDate> Wed, 29 Jan 2025 06:00:00 -0500</pubDate><dc:creator> minglei li</dc:creator><dc:creator> Zongming Han</dc:creator><dc:creator> Jinlei li</dc:creator><dc:creator> Qianyun Wang</dc:creator><dc:creator> Zufang LV</dc:creator><dc:date> 2025-01-29</dc:date><dc:source>免疫学领域</dc:source><dc:title>鲤鱼VIII抗体相关相关的自身免疫性小脑共济失调，&lt;em>; &lt;em>;支原体肺炎&lt;/em>;感染：病例报告</dc:title><dc:identifier>PMID：39877367</dc:identifier><dc:identifier> PMC：PMC11772169</dc:identifier><dc:identifier> doi：10.3389/fimmu.2024.1480212</dc:identifier></item><item><title> Omicron感染后对SARS-COV-2尖峰的免疫反应的比较或Omicron BA.4/5肾脏移植受体中的疫苗接种</title><link/>https://pubmed.ncbi.nlm.nih.gov/39877366/?utm_source=chrome&amp;utm_medium = rsss＆utm_campaign = Journals&amp;utm_campaign = Journals&amp;utm_content = 101560960＆fc = none＆fc = none&amp;ff = none＆fff = = = = = = = = = = = = = = = = = = = = = = == 4<description>结论：BA.4/5疫苗改善了针对BA.4/5变体的中和活性，但没有针对KTR中的XBB.1.5变体。相反，Omicron感染更有效地增强了T细胞和体液反应，显示出对XBB.1.5的功效。 These findings suggest that infection-induced immunity associates with greater protection than vaccination against future variants in KTRs. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Jan 14;15:1476294. doi: 10.3389/fimmu.2024.1476294. eCollection 2024.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: The emergence of novel SARS-CoV-2 variants challenges immunity, particularly among immunocompromised kidney transplant recipients (KTRs). To address this, vaccines have been adjusted to circulating variants. Despite intensive vaccination efforts, SARS-CoV-2 infections surged among KTRs during the Omicron wave, enabling a direct comparison of variant-specific immunity following-vaccination against Omicron BA.4/5 or Omicron infection in KTRs. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: 98 SARS-CoV-2 naïve KTRs who had received four vaccine doses were studied. Before and after a 5th antigen exposure, either via the bivalent vaccine composed of ancestral SARS-CoV-2 and Omicron BA.4/5 (29 KTRs) or via natural infection with Omicron (38 BA.4/5, 31 BA.1/2), spike-specific T cells were quantified using Elispot and serum pseudovirus neutralizing activity was assessed against the ancestral Wuhan strain, BA.5 and XBB.1.5. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Compared to BA.4/5 vaccination, spike-specific T-cell responses and neutralization activity were higher up to six months post-Omicron infection and reached levels similar to healthy controls. Vaccinated KTRs showed modestly boosted neutralization activity against the Wuhan strain and BA.5, but not XBB.1.5. Baseline immunity correlated with immune responses three months post-vaccination and post-infection, indicating a predictive value for peak immune responses. Tixagevimab/Cilgavimab treatment was associated with robust neutralization of the Wuhan strain, but ineffective against XBB.1.5. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: The BA.4/5 vaccine improved neutralizing activity against the BA.4/5 variant, but not against the subsequently circulating XBB.1.5 variant in KTRs. Conversely, omicron infection boosted T cells and humoral responses more effectively, showing efficacy against XBB.1.5. These findings suggest that infection-induced immunity associates with greater protection than vaccination against future variants in KTRs.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39877366/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">39877366</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11772199/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">PMC11772199</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1476294>10.3389/fimmu.2024.1476294</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39877366</guid><pubDate> Wed, 29 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Inga Tometten</dc:creator><dc:creator> Tobias Brandt</dc:creator><dc:creator> Maike Schlotz</dc:creator><dc:creator> Ricarda Stumpf</dc:creator><dc:creator> Sinje Landmann</dc:creator><dc:creator> Marta Kantauskaite</dc:creator><dc:creator> Joshua Lamberti</dc:creator><dc:creator> Jonas Hillebrandt</dc:creator><dc:creator>丽莎·穆勒（LisaMüller）</dc:creator><dc:creator> Margarethe Kittel</dc:creator><dc:creator> Katrin Ivens</dc:creator><dc:creator> Henning Gruell</dc:creator><dc:creator> Anja Voges</dc:creator><dc:creator> Heiner Schaal</dc:creator><dc:creator> Nadine Lübke</dc:creator><dc:creator> Eva Königshausen</dc:creator><dc:creator> Lars Christian Rump</dc:creator><dc:creator> Florian Klein</dc:creator><dc:creator> Johannes Stegbauer</dc:creator><dc:creator> Jörg Timm</dc:creator><dc:date> 2025-01-29</dc:date><dc:source>免疫学领域</dc:source><dc:title>Comparison of immune responses to SARS-CoV-2 spike following Omicron infection or Omicron BA.4/5 vaccination in kidney transplant recipients</dc:title><dc:identifier> pmid:39877366</dc:identifier><dc:identifier> pmc:PMC11772199</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1476294</dc:identifier></item><item><title> Fatty acid synthase inhibition improves hypertension-induced erectile dysfunction by suppressing oxidative stress and NLRP3 inflammasome-dependent pyroptosis through activating the Nrf2/HO-1 pathway</title><link/> https://pubmed.ncbi.nlm.nih.gov/39877365/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250129170938&amp;v=2.18.0.post9+e462414<description> CONCLUSION: These findings suggest that Fasn inhibition may offer a promising therapeutic strategy for hypertension-induced ED by alleviating oxidative stress and suppressing NLRP3 inflammasome-dependent endothelial cell pyroptosis via activation of the Nrf2/HO-1 pathway. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Jan 14;15:1532021. doi: 10.3389/fimmu.2024.1532021. eCollection 2024.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Erectile dysfunction (ED) is a prevalent male sexual disorder, commonly associated with hypertension, though the underlying mechanisms remain poorly understood. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: This study aims to explore the role of Fatty acid synthase (Fasn) in hypertension-induced ED and evaluate the therapeutic potential of the Fasn inhibitor C75. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MATERIALS AND METHODS: Erectile function was assessed by determining the intracavernous pressure/mean arterial pressure (ICP/MAP) ratio, followed by the collection of cavernous tissue for transcriptomic and non-targeted metabolomic analyses. <i>In vitro</i> , a concentration of 10 <sup>-6</sup> M angiotensin II (Ang II) was applied to rat aortic endothelial cells (RAOECs) to establish a model of hypertension. <i>In vivo</i> , spontaneously hypertensive rats (SHR) were randomly divided into two groups. The SHR+C75 group received intraperitoneal injections of C75 at a dose of 2 mg/kg once a week. After five weeks of treatment, the erectile function of the rats was assessed, and penile tissues were harvested for further analysis. Molecular and protein expression were assessed using Western blotting, qRT-PCR, immunofluorescence staining, and immunohistochemistry. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: The SHR exhibited ED, indicated by reduced maximum ICP/MAP ratios. Histologically, corpus cavernosum tissue of SHR showed elevated fibrosis and endothelial dysfunction. Additionally, increased expression of the NLRP3 inflammasome, Caspase-1, GSDMD, and the pro-inflammatory cytokines IL-1β and IL-18 was observed. Multi-omics analysis revealed significant enrichment in lipid metabolic pathways, with Fasn identified as a hub gene. <i>In vitro</i> , siFasn and C75 enhanced antioxidant markers Nrf2 and HO-1, reduced ROS accumulation, and suppressed NLRP3 and GSDMD levels. <i>In vivo</i> , C75 treatment restored endothelial function and reversed erectile dysfunction, accompanied by decreased oxidative stress and pyroptosis in the penile corpus cavernosum. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: These findings suggest that Fasn inhibition may offer a promising therapeutic strategy for hypertension-induced ED by alleviating oxidative stress and suppressing NLRP3 inflammasome-dependent endothelial cell pyroptosis <i>via</i> activation of the Nrf2/HO-1 pathway.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39877365/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">39877365</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11772187/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">PMC11772187</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1532021>10.3389/fimmu.2024.1532021</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39877365</guid><pubDate> Wed, 29 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Jiaochen Luan</dc:creator><dc:creator> Mengchi Yu</dc:creator><dc:creator> Qi Gu</dc:creator><dc:creator> Xuan Zhou</dc:creator><dc:creator> Yunqiang Shao</dc:creator><dc:creator>汤陈</dc:creator><dc:creator>Jiayi Zhang</dc:creator><dc:creator> Zheng Zhu</dc:creator><dc:creator> Ninghong Song</dc:creator><dc:creator>耶杨</dc:creator><dc:date>2025-01-29</dc:date><dc:source>免疫学领域</dc:source><dc:title>Fatty acid synthase inhibition improves hypertension-induced erectile dysfunction by suppressing oxidative stress and NLRP3 inflammasome-dependent pyroptosis through activating the Nrf2/HO-1 pathway</dc:title><dc:identifier> pmid:39877365</dc:identifier><dc:identifier> pmc:PMC11772187</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1532021</dc:identifier></item><item><title> CAR-macrophages: tailoring cancer immunotherapy</title><link/> https://pubmed.ncbi.nlm.nih.gov/39877364/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250129170938&amp;v=2.18.0.post9+e462414<description>没有抽象</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Jan 14;15:1532833. doi: 10.3389/fimmu.2024.1532833. eCollection 2024.</p><p><b>没有抽象</b></p><p style="color: lightgray">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39877364/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">39877364</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11772431/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">PMC11772431</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1532833>10.3389/fimmu.2024.1532833</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39877364</guid><pubDate> Wed, 29 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Dewan Chettri</dc:creator><dc:creator> Bibhu Prasad Satapathy</dc:creator><dc:creator> Rohit Yadav</dc:creator><dc:creator> Vivek Uttam</dc:creator><dc:creator> Aklank Jain</dc:creator><dc:creator> Hridayesh Prakash</dc:creator><dc:date> 2025-01-29</dc:date><dc:source>免疫学领域</dc:source><dc:title>CAR-macrophages: tailoring cancer immunotherapy</dc:title><dc:identifier> pmid:39877364</dc:identifier><dc:identifier> pmc:PMC11772431</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1532833</dc:identifier></item><item><title> Serum lipid profile in systemic lupus erythematosus</title><link/> https://pubmed.ncbi.nlm.nih.gov/39877363/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250129170938&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: Dyslipidemia is present in SLE. There was a significant association between SLE disease activity and TC, TG, and HDL. The exact pathogenesis of metabolic disorders in SLE needs to be further addressed. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Jan 14;15:1503434. doi: 10.3389/fimmu.2024.1503434. eCollection 2024.</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Dyslipidemia presents in various autoimmune diseases, and the serum lipid profile in systemic lupus erythematosus (SLE) has not yet been clearly defined. This study aims to evaluate the level of serum lipids in patients with SLE. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: A case-control study evaluated four conventional sera lipids-total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL)-in patients with SLE compared to healthy controls (HCs). Correlations between serum lipids and clinical characteristics were analyzed in patients with SLE. A systematic review and meta-analysis were conducted to assess the epidemiology of lipid profiles in patients with SLE, and a random-effects meta-analysis was performed for data synthesis. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: TC and TG were elevated significantly, and HDL decreased in patients with SLE compared to HCs. Elevated lipids were associated with progressive disease activity. TC, TG, and HDL were elevated in patients with SLE and were associated with decreased IgG, increased 24-h proteinuria, white blood cells (WBCs), and neutrophils. Decreased HDL and increased TG were associated with an increase in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Patients with SLE who took glucocorticoids (GCs) may have experienced increases in TC and TG, while those who took hydroxychloroquine (HCQ) may have experienced increases in TC and HDL. Eleven eligible studies including the present study on associations between serum lipids and SLE were reviewed by the meta-analysis. The results demonstrated elevated TC (MD = 0.85, 95% CI 0.82 to 0.89, <i>p</i> &lt; 0.00001) and TG (MD = 0.96, 95% CI 0.94 to 0.99, <i>p</i> &lt; 0.00001) levels in SLE, while HDL decreased (MD = -0.19, 95% CI -0.20 to -0.17, <i>p</i> &lt; 0.00001). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Dyslipidemia is present in SLE. There was a significant association between SLE disease activity and TC, TG, and HDL. The exact pathogenesis of metabolic disorders in SLE needs to be further addressed.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/39877363/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">39877363</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11772162/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250129170938&v=2.18.0.post9+e462414">PMC11772162</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2024.1503434>10.3389/fimmu.2024.1503434</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:39877363</guid><pubDate> Wed, 29 Jan 2025 06:00:00 -0500</pubDate><dc:creator> Jingxiu Xuan</dc:creator><dc:creator> Chaoqiong Deng</dc:creator><dc:creator> Huiqin Lu</dc:creator><dc:creator> Yan He</dc:creator><dc:creator> Jimin Zhang</dc:creator><dc:creator> Xiaoli Zeng</dc:creator><dc:creator> Yuechi Sun</dc:creator><dc:creator> Shiju Chen</dc:creator><dc:creator> liu</dc:creator><dc:date> 2025-01-29</dc:date><dc:source>免疫学领域</dc:source><dc:title>Serum lipid profile in systemic lupus erythematosus</dc:title><dc:identifier> pmid:39877363</dc:identifier><dc:identifier> pmc:PMC11772162</dc:identifier><dc:identifier> doi:10.3389/fimmu.2024.1503434</dc:identifier></item></channel></rss>